long intergenic non-protein coding RNA 1916Genealiases: []
Q-omics provides the consensus-scored LINC01916 profile across patient tissues and cancer cell-line models. LINC01916 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC01916 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, LINC01916 RNA expression shows 10,594 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, HNSC, and TGCT as cancer lineages where LINC01916 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01916 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01916 survival associations across molecular data types. LINC01916 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01916 RNA expression–survival associations across cancer types. High LINC01916 expression shows unfavorable associations in LUAD, KICH, HNSC, READ and ESCA, but favorable associations in ACC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC01916 RNA expression.
This table summarizes LINC01916 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01916. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01916 shows lower tumor expression in HNSC, KIRC, BLCA, KICH, BRCA and KIRP. The HNSC box plot shows higher LINC01916 RNA expression in normal versus tumor tissue (log2 FC = −0.133, t-test p = .015).
This table shows molecular features associated with LINC01916 in patient tissues and cancer cell lines. In patient samples, LINC01916 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
